Abbott has launched a clinical trial to evaluate the ability of its CardioMEMS HF System to improve survival and quality of life in patients with New York Heart Association (NYHA) Class II – IV heart failure.

The system includes a small pressure-sensing device that can be directly implanted, during a minimally invasive procedure, into the pulmonary artery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is designed to enable remote, wireless monitoring of blood pressure changes before the progression of symptoms. Data captured by the device is expected to help physicians to proactively manage medications and treatment plans for patients.

The prospective GUIDE-HF trial is set to recruit 3,600 volunteers at 140 North American hospitals.

“The system includes a small pressure-sensing device that can be directly implanted, during a minimally invasive procedure, into the pulmonary artery.”

Enrolment criterion for the trial is stage C, NYHA Class II-IV heart failure patients with enhanced brain-type natriuretic peptide (BNP) levels or previous heart failure hospitalisations over the past 12 months.

Abbott Heart Failure business divisional vice-president and medical director Philip Adamson said: “Data suggests that proactively managing people living with heart failure may change the course of the disease’s progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The CardioMEMS HF System is the first-of-its-kind approach to redefine heart failure management. The GUIDE-HF study sets out to make this technology available to an expanded group of people who could benefit from it.”

Previously, the CardioMEMS HF System was reported to have significantly decreased hospital admissions due to heart failure and enhanced the quality of life for people with NYHA Class III heart failure.